Skip to content

Study on the relationship between impaired white matter cholinergic pathway and clinical features and cognitive function of elderly depression

Study on the relationship between impaired white matter cholinergic pathway and clinical features and cognitive function of elderly depression

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110045
Enrollment
Unknown
Registered
2025-09-29
Start date
2024-04-18
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Late life depression

Interventions

Elderly patients with depression:None
Control group :None

Sponsors

Beijing Anding Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: Elderly patients with depression: 1. All participants meet the diagnostic criteria for major depressive disorder according to DSM-IV; 2. First episode of depression occurring after age 60; 3. Age >= 60 years, right-handed, with at least a junior high school education; 4. Written informed consent has been obtained; 5. Total score on the 17-item Hamilton Depression Rating Scale (HAMD-17) >= 17. Control Group: 1. Age >= 60 years, right-handed, with education level of junior high school or higher; 2. No significant somatic illnesses or psychiatric disorders meeting diagnostic criteria; 3. No personal or family history of psychiatric disorders; 4. Written informed consent has been obtained.

Exclusion criteria

Exclusion criteria: 1. Presence of conditions that interfere with neuropsychological assessment, such as severe hearing or visual impairment, aphasia, or dominant-side hemiplegia; 2. No use of medications that may affect cognitive function; 3. No concurrent severe failure of vital organs, including heart, liver, or kidney; 4. No history of prior cerebrovascular events; 5. No cognitive impairment due to large infarcts in critical isolated regions, or neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, or Huntington’s disease; 6. No cognitive impairment due to other causes, including traumatic brain injury, tumors, infections, metabolic disorders, normal pressure hydrocephalus, folate or vitamin B12 deficiency, or hypothyroidism; 7. Exclusion of other white matter diseases; 8. No history of epilepsy, use of special medications, or alcohol/drug dependence; 9. No contraindications to MRI, including cardiac pacemakers, neural stimulators, artificial metallic heart valves, intracorporeal ferromagnetic foreign bodies, severe claustrophobia, or marked hyperthermia; 10. No electroconvulsive therapy (ECT) within the past three months.

Design outcomes

Primary

MeasureTime frame
Fractional anisotropy;Mean diffusion;

Secondary

MeasureTime frame
Fasting Plasma Glucose;Cholesterol;High-density Lipoprotein;Triglycerides;Homocysteine;

Countries

China

Contacts

Public ContactZhang Xinqiao

Beijing Anding Hospital Affiliated to Capital Medical University

7581752@qq.com+86 136 9914 3282

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026